The acquisition of TriviumVet brings the addition of an innovative new product, Felycin®-CA1, to the PRN® Pharmacal portfolio of products. Felycin is the only FDA conditionally approved drug for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), one of the most common and life-threatening diseases in cats. TriviumVet adds brings a robust pipeline of therapeutics including feline chronic kidney disease, as well as pain management and gastric ulcers in canines.
Source: PR Newswire, May 5, 2025. Link. Felycin®-CA1 will be available for veterinary customers to order by August of this year. To ensure customer engagement while building pet owner awareness for a successful product launch, PRN® Pharmacal will expand its team by hiring over 50 additional employees.